Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study - Archive ouverte HAL Access content directly
Journal Articles EBioMedicine Year : 2022

Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study

(1) , (2) , (1) , (2) , (3) , (1) , (4) , (5) , (6) , (2) , (6) , (7) , (8) , (8) , (8) , (7) , (9) , (6) , (6) , (3) , (7) , (6) , (8) , (10)
1
2
3
4
5
6
7
8
9
10
Odile Launay
  • Function : Author
Bastiaan Jansen
  • Function : Author
SGS

Abstract

Background V591 (TMV-083) is a live recombinant measles vector-based vaccine candidate expressing a pre-fusion stabilized SARS-CoV-2 spike protein. Methods We performed a randomized, placebo-controlled Phase I trial with an unblinded dose escalation and a dou- ble-blind treatment phase at 2 sites in France and Belgium to evaluate the safety and immunogenicity of V591. Ninety healthy SARS-CoV-2 sero-negative adults (18-55 years of age) were randomized into 3 cohorts, each compris- ing 24 vaccinees and 6 placebo recipients. Participants received two intramuscular injections of a low dose vaccine (1 £ 105 median Tissue Culture Infectious Dose [TCID50]), one or two injections of a high dose vaccine (1 £ 106 TCID50), or placebo with a 28 day interval. Safety was assessed by solicited and unsolicited adverse events. Immuno- genicity was measured by SARS-CoV-2 spike protein-binding antibodies, neutralizing antibodies, spike-specific T cell responses, and anti-measles antibodies. ClinicalTrials.gov, NCT04497298. Findings Between Aug 10 and Oct 13, 2020, 148 volunteers were screened of whom 90 were randomized. V591 showed a good safety profile at both dose levels. No serious adverse events were reported. At least one treatment- related adverse event was reported by 15 (20.8%) participants receiving V591 vs. 6 (33.3%) of participants receiving placebo. Eighty-one percent of participants receiving two injections of V591 developed spike-binding antibodies after the second injection. However, neutralizing antibodies were detectable on day 56 only in 17% of participants receiv- ing the low dose and 61% receiving the high dose (2 injections). Spike-specific T cell responses were not detected. Pre-existing anti-measles immunity had a statistically significant impact on the immune response to V591, which was in contrast to previous results with the measles vector-based chikungunya vaccine. Interpretation While V591 was generally well tolerated, the immunogenicity was not sufficient to support further development.
Fichier principal
Vignette du fichier
Launay-2022_V591 clinical trial.pdf (1.16 Mo) Télécharger le fichier
Vignette du fichier
Launay-2022_V591 clinical trial_Supplementary data-Study Protocol.pdf (1.66 Mo) Télécharger le fichier
Vignette du fichier
Launay-2022_V591 clinical trial_Supplementary Figure_CD4 and CD8 T cell responses.pdf (432.33 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

pasteur-03748335 , version 1 (09-08-2022)

Licence

Attribution - CC BY 4.0

Identifiers

Cite

Odile Launay, Cécile Artaud, Marie Lachâtre, Mohand Ait-Ahmed, Jelle Klein, et al.. Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study. EBioMedicine, 2022, 75, pp.103810. ⟨10.1016/j.ebiom.2021.103810⟩. ⟨pasteur-03748335⟩
52 View
15 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More